Bwx technologies, inc. plans to produce the medical radioisotope germanium-68

Bwx technologies, inc. announced that it plans to produce the medical radioisotope germanium-68 (ge-68) with a focus on addressing a growing global demand for the product. bwxt’s isotope technologies group in canada has developed proprietary manufacturing technology to produce high purity ge-68 and is in the process of scaling up its capacity to move into full production in 2020 to address growing global customer demands. ge-68 will be produced using cyclotrons at bwxt’s vancouver facility located on the triumf site. triumf, which is canada’s particle accelerator center, and bwxt’s medical isotopes group have been working together to support medical isotope production for over 40 years. bwxt’s ge-68 product will be used in gallium-68 (ga-68) generators, a source of the diagnostic radioisotope ga-68. using specific disease-targeting molecules, ga-68 provides diagnoses and enables treatment planning using positron emission tomography (pet). diagnostic applications for ga-68 include prostate cancer and neuroendocrine tumors. in addition, a number of other therapeutic and ga-68 imaging agents are in various stages of development and clinical trials that are expected to result in a further increase in demand for ga-68. ge-68 is the third new medical radioisotope development project underway at bwxt. in 2018, the company announced that it had developed an innovative and unique process to manufacture molybdenum-99 (mo-99), and in late september of this year, bwxt announced the availability of its generic version of indium in-111 oxyquinoline solution. bwxt also markets four other radiochemical solutions (indium-111, iodine-123, palladium-103 and strontium-82).
BWXT Ratings Summary
BWXT Quant Ranking